Ovid Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Ovid Therapeutics

16/08/2021 11:57

* Ovid Therapeutics Inc  OVID.OQ  reported a quarterly adjusted
loss of 23 cents​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 16 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Ovid Therapeutics Inc's reported EPS for the quarter was a
loss of 23 cents​.
* The mean earnings estimate of analysts had fallen by
about 0.4% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Ovid Therapeutics Inc shares had risen by 3.3% this
quarter and gained 74.9% so far this year.
* The company reported a quarterly loss of $15.79 million.
* Wall Street's median 12-month price target for Ovid
Therapeutics Inc is $4.25 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 16 at 10:57 a.m.  ​All
figures in US dollars unless otherwise stated